In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 131 to 140 of 294

TitleTypeExpected publication date
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]Technology appraisal guidance
Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]Technology appraisal guidanceTBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]Technology appraisal guidanceTBC
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]Technology appraisal guidance
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]Technology appraisal guidanceTBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]Technology appraisal guidanceTBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340]Technology appraisal guidanceTBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]Technology appraisal guidanceTBC
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All